<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89182">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02096952</url>
  </required_header>
  <id_info>
    <org_study_id>2014P000501</org_study_id>
    <nct_id>NCT02096952</nct_id>
  </id_info>
  <brief_title>Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD</brief_title>
  <official_title>Open-Label Treatment Trial to Assess the Short-Term Tolerability, Safety, and Efficacy of Methylphenidate Hydrochloride Extended-Release Liquid Formulation in High-Functioning Autism Spectrum Disorder Adults With Attention-Deficit/Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether methylphenidate hydrochloride extended
      release liquid formulation is safe and effective in the treatment of
      attention-deficit/hyperactivity disorder (ADHD) in high-functioning adults with autism
      spectrum disorders (ASD).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adult ADHD Investigator Symptom Report Scale (AISRS)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Adult ADHD Investigator Symptom Report Scale (AISRS) assesses each of the 18 individual symptoms of ADHD in DSM-IV on a Likert scale from 0 (not present) to 3 (severe), with a total possible score of 54.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Attention-deficit/Hyperactivity Disorder</condition>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Methylphenidate extended-release liquid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylphenidate extended-release liquid formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate extended-release liquid formulation</intervention_name>
    <arm_group_label>Methylphenidate extended-release liquid</arm_group_label>
    <other_name>Methylphenidate extended-release liquid formulation</other_name>
    <other_name>Quillivant extended release</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female participants between 18 and 25 years of age (inclusive)

          -  Fulfills Diagnostic and Statistical Manual 5 (DSM-5) diagnostic criteria for autism
             spectrum disorder as established by the clinical diagnostic interview and Autism
             Diagnostic Observation Schedule (ADOS)

          -  Fulfills DSM-5 diagnostic criteria for Attention Deficit/Hyperactivity Disorder
             (ADHD) as established by the clinical diagnostic interview and confirmed by the
             Kiddie Schedule for Affective Disorders and Schizophrenia-Epidemiological Version
             (K-SADS-E) ADHD module

          -  Participants with at least moderately severe symptoms of Autism Spectrum Disorder
             (ASD) as demonstrated by Social Responsiveness Scale (SRS) raw score greater than or
             equal to 85 and Clinical Global Impression (CGI)-ASD severity score greater than or
             equal to 4

          -  Participants with at least moderately severe symptoms of ADHD as assessed by AISRS
             score greater than or equal to 24 and CGI-ADHD severity score greater than or equal
             to 4

          -  Each participant must understand the nature of the study. The participant must sign
             an Institutional Review Board-approved informed consent form before initiation of any
             study procedures.

          -  Participant must have a level of understanding sufficient to communicate with the
             investigator and study coordinator, and to cooperate with all tests and examinations
             required by the protocol.

          -  Participant must be able to participate in mandatory blood draws.

          -  Participant with major mood and/or anxiety disorders will be allowed to participate
             in the study provided they do not meet any exclusionary criteria.

        Exclusion Criteria:

          -  Impaired intellectual capacity (Intelligence Quotient [IQ] less than 85; one standard
             deviation below the mean IQ)

          -  Participant is unable to communicate due to delay in, or total lack of, spoken
             language development (grossly impaired language skills)

          -  Clinically unstable psychiatric conditions or judged to be at serious safety risk to
             self (suicidal risk) or others (within past 30 days).

          -  Current diagnosis (within past 30 days) of an anxiety, mood, or psychotic disorder.

          -  History of substance use (except nicotine or caffeine) within past 3 months
             (inclusive) or with urine drug screen positive for substances of abuse

          -  Subjects with a medical condition or treatment that will either jeopardize subject
             safety or affect the scientific merit of the study, including:

          -  Pregnant or nursing females or females with a positive urine pregnancy test.

          -  Uncorrected hypothyroidism or hyperthyroidism.

          -  History of non-febrile seizures within last 1 month without a clear and resolved
             etiology.

          -  History of renal or hepatic impairment.

          -  Serious, unstable systemic illness

          -  Personal history of cardiac disease or a family history of non-geriatric cardiac
             disease or death

          -  Clinically significant abnormal baseline laboratory values which include the
             following: Values         more than 20% above the upper range of the laboratory
             standard for a basic metabolic screen.

          -  Systolic and diastolic blood pressure parameters above 140 and 90, respectively.

          -  Resting heart rate outside of 60-100 beats per minute.

          -  Abnormal electrocardiogram (ECG) parameters defined as a corrected QT interval
             greater than 460 milliseconds, QRS interval greater than 120 milliseconds, and/or PR
             interval greater than 200 milliseconds.

          -  ECG evidence of ischemia or arrhythmia as reviewed by an independent cardiologist.

          -  Participant with a history of non-response to adequate trial of methylphenidate
             (therapeutic dose for an adequate duration) as determined by clinician.

          -  History of intolerance or an allergic reaction to methylphenidate.

          -  Current treatment with first- or second-generation antipsychotic medications or
             stimulant class of anti-ADHD medications.

          -  Current treatment with monoamine oxidase inhibitors (MAOIs)

          -  Current treatment with a psychotropic medication on a dose that has not been stable
             for at least 4 weeks prior to baseline visit.

          -  Investigator and his/her immediate family, defined as the investigator's spouse,
             parent, child, grandparent, or grandchild.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gagan Joshi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephannie Furtak</last_name>
    <phone>617-724-2344</phone>
    <email>sfurtak1@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rebecca Grossman</last_name>
    <phone>617-643-1432</phone>
    <email>rgrossman1@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephannie Furtak</last_name>
      <phone>617-724-2344</phone>
      <email>sfurtak1@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Grossman</last_name>
      <phone>617-643-1432</phone>
      <email>rgrossman1@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gagan Joshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Gagan Joshi, MD</investigator_full_name>
    <investigator_title>Assistant professor of Psychiatry, Harvard Medical School; Director, Autism Spectrum Disorder Clinical &amp; Research Program, Pediatric Psychopharmacology</investigator_title>
  </responsible_party>
  <keyword>Attention-deficit/hyperactivity disorder</keyword>
  <keyword>ADHD</keyword>
  <keyword>Autism spectrum disorder</keyword>
  <keyword>ASD</keyword>
  <keyword>High-functioning ASD</keyword>
  <keyword>Asperger's disorder</keyword>
  <keyword>Asperger's</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
